Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 13:101938.
doi: 10.1016/j.jocmr.2025.101938. Online ahead of print.

Mitral Annular Disjunction in Marfan Syndrome: A Multicenter Cardiovascular Magnetic Resonance Study

Affiliations
Free article

Mitral Annular Disjunction in Marfan Syndrome: A Multicenter Cardiovascular Magnetic Resonance Study

Kenan Kaya et al. J Cardiovasc Magn Reson. .
Free article

Abstract

Background: Data on the prevalence of mitral annular disjunction (MAD) in Marfan syndrome (MFS) based on cardiovascular magnetic resonance (CMR) is sparse. The purpose of this study was to assess prevalence, extent, and distribution of MAD in MFS using CMR and to examine its association with left heart parameters, aortic dimensions, and cardiovascular events.

Methods: This retrospective multicenter study included CMR studies of patients treated for MFS at four tertiary care medical centers with a (likely) pathogenic fibrillin-1 gene variant. Two radiologists (five and eight years of experience in CMR) evaluated datasets for MAD (at four points around the annulus, including measurement of extent) and mitral valve prolapse (MVP). Further assessment comprised volumetric and functional analysis of the left ventricle (LV), left atrial size, and aortic root diameters. Cardiovascular events included aortic (aortic surgery or aortic dissection), arrhythmic (sustained ventricular tachycardia or sudden cardiac death), and mitral events (mitral valve surgery, MVS).

Results: Among 91 patients (28.9±14.0 years, 47.3% female), 81.3% had MAD (extent: 6.1±2.6mm). MAD was mostly found at the inferior insertion (72.5% of patients) and usually affected all sites (39.6% of patients). Left heart parameters and aortic dimensions did not differ between MAD and no MAD groups (P>0.05). MAD extent and localizations showed significant correlations with LV dilatation (e.g., inferior MAD: r=0.62 for end-diastolic volume index), decreased LV ejection fraction (e.g., anterolateral MAD: r=-0.46), and MVP (e.g., MAD distance: r=0.83), which was found in 44.6% of patients with MAD while only affecting 11.8% without MAD (P=0.017). Based on receiver operating characteristic analysis for the prediction of MVP prevalence, a threshold of 7.1mm MAD extent was identified as the optimal cut-off value (sensitivity: 77.1%, specificity: 89.3%). Additionally, subgroup analysis applying different thresholds of MAD extent revealed a significantly larger displacement of MVP and LV volumes as well as higher aortic root z scores for a threshold of ≥ 8mm. After a mean follow-up of 4.0±3.0 years, cardiovascular events [aortic: n=13 (14.3%), arrhythmic: n=2 (2.2%), and mitral: n=2 (2.2%) of patients] did not differ significantly (all P>0.05) between no MAD and MAD groups regardless of applied thresholds although MVS was observed exclusively in patients with MAD.

Conclusion: The high prevalence, large extent, and predominantly pan-annular distribution of MAD suggest a systemic annular pathology in MFS. Overall presence of MAD was not associated with changes to left heart parameters, aortic dimensions, and cardiovascular events. However, MAD, taking into account its extent and affected insertion sites, could serve as a potential marker of disease progression given the shown association of localizations and distance with LV dysfunction and remodeling as well as aortic enlargement and the formation of MVP.

Keywords: Marfan syndrome; cardiovascular magnetic resonance; connective tissue disorder; mitral annular disjunction; mitral valve prolapse.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Kenan Kaya reports administrative support and article publishing charges were provided by University Hospital Cologne Institute of Diagnostic and Interventional Radiology. Roman Johannes Gertz reports financial support was provided by Philips Healthcare Informatics Inc. Roman Johannes Gertz reports financial support was provided by Guerbet. David Maintz reports financial support was provided by Philips Healthcare Informatics Inc. Kilian Weiss reports financial support was provided by Philips Healthcare Informatics Inc. Tilman Emrich reports was provided by Siemens Healthineers AG. Tilman Emrich reports financial support was provided by Circle Cardiovascular Imaging Inc. Julian A. Luetkens reports financial support was provided by Bayer HealthCare AG. Julian A. Luetkens reports financial support was provided by GE Healthcare. Julian A. Luetkens reports financial support was provided by Novartis Pharmaceuticals Corporation. Julian A. Luetkens reports financial support was provided by Philips Healthcare Informatics Inc. Julian A. Luetkens reports financial support was provided by Siemens Healthineers AG. Lenhard Pennig reports financial support was provided by Philips Healthcare Informatics Inc. Lenhard Pennig reports financial support was provided by Guerbet. Kenan Kaya reports a relationship with University Hospital Cologne Institute of Diagnostic and Interventional Radiology that includes: employment. Kilian Weiss reports a relationship with Philips that includes: employment and equity or stocks. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Competing interests Roman Johannes Gertz: Speakers bureau for Philips Healthcare and Guerbet GmbH. David Maintz: Speakers bureau for Philips Healthcare. Kilian Weiss: Employee, Philips GmbH. Tilman Emrich: Speakers bureau and institutional research support: Siemens Healthineers, Consultant: Circle Cardiovascular Imaging Julian A. Luetkens: Scientific advisory board of Bayer Healthcare; Speakers bureau for Bayer Healthcare, GE HealthCare, Novartis, Philips Healthcare, and Siemens Healthineers. Lenhard Pennig: Speakers bureau for Philips Healthcare and Guerbet GmbH.

LinkOut - more resources